Objective: To investigate the radiosensitized target of Fuzheng Zengxiao Formula (扶正增效方). Methods: The pulmonary adenocarcinoma (PAa) nude mice of tumor transplantation model were prepared and divided into four g...Objective: To investigate the radiosensitized target of Fuzheng Zengxiao Formula (扶正增效方). Methods: The pulmonary adenocarcinoma (PAa) nude mice of tumor transplantation model were prepared and divided into four groups: Group I (blank control group, n=10), Group II (simple radiotherapy group, n=10), Group III (radiotherapy plus Fuzheng Zengxiao Formula, n=10) and Group IV (radiotherapy plus metronidazole, n=10). Radiation of Х-rays was given to the tumors in Group I, II and III when they were averagely about 1 centimetre in diameter. 23 hours later, the tumors were taken, the total proteins were extracted, and the protein contents were determined. The proteins were isolated with two dimensional gel electrophoresis, and the differentially expressed proteins were analyzed with mass spectrometry and identified by protein database. Results: Six significant proteins, including apolipoprotein E, ceratin75, S100A9, cyclophilin A, S100A10 and hemoglobin, were determined. Compared with Group I, apolipoprotein E and ceratin75 highly expressed in the Group II; compared with Group II, S100A9, cyclophilin A and hemoglobin had high expression in the Group III; compared with Group II, S100A9, cyclophilin A, S100A10 and hemoglobin had high expression in the Group IV; compared with Group IV, S100A9 and S100A10 had low expression and hemoglobin had high expression in Group III. Conclusion: The radiosensitization of Fuzheng Zengxiao Formula is related with the improvement of hypoxia state; and possibly S100A9 and cyclophilin A are the target proteins of Fuzheng Zengxiao Formula in radiosensitization.展开更多
OBJECTIVE:To investigate the effect of the decoction of Fuzheng Jiedu Xiaoji formula(扶正解毒消积方,FJXF)plus chemoembolization(TACE)on primary liver cancer(PLC)in patients,and study the underlying mechanism.METHODS:P...OBJECTIVE:To investigate the effect of the decoction of Fuzheng Jiedu Xiaoji formula(扶正解毒消积方,FJXF)plus chemoembolization(TACE)on primary liver cancer(PLC)in patients,and study the underlying mechanism.METHODS:Patients with PLC who met the inclusion criteria were randomized into case group and control group.The case group was treated with FJXF combined with TACE.The control group was treated with TACE alone.The short-term clinical effect was evaluated;liver biochemistry,liver function index and multidrug resistance-associated indicators were detected.RESULTS:FJXF combined with TACE in the case group significantly increased the disease control rate than TACE alone in the control group(83.3%vs 61.1%).There was a reduction in the serum alpha-fetoprotein at 8 weeks after treatment in each group,while no difference between the two groups.The same trend can be observed for transaminase and direct bilirubin in both groups.In the case group,it showed a significant increase for albumin at 8 weeks after treatment,while no change in the control group.Multidrug resistanceassociated indicators for multidrug resistance protein 1 and p-glycoprotein were upregulated in the case group but remained stable in the control group.CONCLUSIONS:FJXF combined TACE had a better short-term effect than TACE alone in patients with PLC.The potential mechanism was probably associated with alleviated multidrug resistance induced by FJXF.Additionally,FJXF didn’t increase the risk of liver damage in the combined therapy.展开更多
目的扶正化瘀方治疗子宫内膜异位症(EM)具有明确的临床疗效,在前期研究中证实,可能与抑制血管生成相关,本研究聚焦于这一研究热点,探索扶正化瘀方治疗EM的作用机制。方法本研究分为两个部分,第一部分进行生物信息学分析,获取扶正化瘀方...目的扶正化瘀方治疗子宫内膜异位症(EM)具有明确的临床疗效,在前期研究中证实,可能与抑制血管生成相关,本研究聚焦于这一研究热点,探索扶正化瘀方治疗EM的作用机制。方法本研究分为两个部分,第一部分进行生物信息学分析,获取扶正化瘀方的药物靶点,EM相关差异表达基因及血管生成的靶点,鉴定出前6位“EM核心靶点”,并在GSE58178芯片中获取“EM核心靶点”的正常组与模型组样本的表达矩阵信息,绘制差异分组比较图,构建TFmRNA-miRNA网络,筛选其作用的核心靶点;第二部分进行动物实验验证。通过同种异体子宫内膜移植法建立EM大鼠模型,将模型大鼠分为模型组、中药组及阳性对照组,每组6只,并设置假手术组6只作为对照,灌胃治疗14 d后取材,对血清及内膜组织进行检测,采用酶联免疫吸附测定检测血清糖类抗原125(CA125)、血管内皮生长因子(VEGF)等相关指标水平,采用逆转录实时定量聚合酶链式反应法检测正常/异位内膜组织miR-199a-5p、低氧诱导因子1α(HIF-1α)、VEGF等相关分子mRNA的表达情况。结果通过生物信息学分析得出,在血管生成这一关键环节,扶正化瘀方可能通过下调HIF-1α、VCAM1、STAT3、SERPINE1,上调MMP2、PDCFRB表达起到干预EM血管生成,延缓异位病灶生长的作用,并构建“TF-m RNA-mi RNA网络”,经过动物实验验证,相比于模型组,中药组血清CA125、VEGF水平显著降低,异位病灶体积显著缩小,且miR-199a-5p表达升高,HIF-1α、VEGF表达降低[(9.99±1.01)U/mL vs(14.60±0.65)U/mL,P<0.05;(170.04±29.40)pg/mL vs(245.42±36.10)pg/mL,P<0.05;(6.41±2.11)mm^(3) vs(23.92±4.63)mm^(3),P<0.05;0.80±0.08 vs 0.02±0.01,P<0.05;1.28±0.06 vs 2.21±0.32,P<0.05;1.29±0.23 vs 3.79±0.80,P<0.05]。结论扶正化瘀方可能通过下调HIF-1α、VEGF等因子表达,干预血管生成这一关键环节,缩小EM异位病灶,延缓EM进一步发展。展开更多
基金supported by the National Natural Science Foundation of China (No.30772857)
文摘Objective: To investigate the radiosensitized target of Fuzheng Zengxiao Formula (扶正增效方). Methods: The pulmonary adenocarcinoma (PAa) nude mice of tumor transplantation model were prepared and divided into four groups: Group I (blank control group, n=10), Group II (simple radiotherapy group, n=10), Group III (radiotherapy plus Fuzheng Zengxiao Formula, n=10) and Group IV (radiotherapy plus metronidazole, n=10). Radiation of Х-rays was given to the tumors in Group I, II and III when they were averagely about 1 centimetre in diameter. 23 hours later, the tumors were taken, the total proteins were extracted, and the protein contents were determined. The proteins were isolated with two dimensional gel electrophoresis, and the differentially expressed proteins were analyzed with mass spectrometry and identified by protein database. Results: Six significant proteins, including apolipoprotein E, ceratin75, S100A9, cyclophilin A, S100A10 and hemoglobin, were determined. Compared with Group I, apolipoprotein E and ceratin75 highly expressed in the Group II; compared with Group II, S100A9, cyclophilin A and hemoglobin had high expression in the Group III; compared with Group II, S100A9, cyclophilin A, S100A10 and hemoglobin had high expression in the Group IV; compared with Group IV, S100A9 and S100A10 had low expression and hemoglobin had high expression in Group III. Conclusion: The radiosensitization of Fuzheng Zengxiao Formula is related with the improvement of hypoxia state; and possibly S100A9 and cyclophilin A are the target proteins of Fuzheng Zengxiao Formula in radiosensitization.
基金Supported by Beijing Municipal Administration of Hospitals Incubating Program(No.pz2017029)
文摘OBJECTIVE:To investigate the effect of the decoction of Fuzheng Jiedu Xiaoji formula(扶正解毒消积方,FJXF)plus chemoembolization(TACE)on primary liver cancer(PLC)in patients,and study the underlying mechanism.METHODS:Patients with PLC who met the inclusion criteria were randomized into case group and control group.The case group was treated with FJXF combined with TACE.The control group was treated with TACE alone.The short-term clinical effect was evaluated;liver biochemistry,liver function index and multidrug resistance-associated indicators were detected.RESULTS:FJXF combined with TACE in the case group significantly increased the disease control rate than TACE alone in the control group(83.3%vs 61.1%).There was a reduction in the serum alpha-fetoprotein at 8 weeks after treatment in each group,while no difference between the two groups.The same trend can be observed for transaminase and direct bilirubin in both groups.In the case group,it showed a significant increase for albumin at 8 weeks after treatment,while no change in the control group.Multidrug resistanceassociated indicators for multidrug resistance protein 1 and p-glycoprotein were upregulated in the case group but remained stable in the control group.CONCLUSIONS:FJXF combined TACE had a better short-term effect than TACE alone in patients with PLC.The potential mechanism was probably associated with alleviated multidrug resistance induced by FJXF.Additionally,FJXF didn’t increase the risk of liver damage in the combined therapy.
文摘目的扶正化瘀方治疗子宫内膜异位症(EM)具有明确的临床疗效,在前期研究中证实,可能与抑制血管生成相关,本研究聚焦于这一研究热点,探索扶正化瘀方治疗EM的作用机制。方法本研究分为两个部分,第一部分进行生物信息学分析,获取扶正化瘀方的药物靶点,EM相关差异表达基因及血管生成的靶点,鉴定出前6位“EM核心靶点”,并在GSE58178芯片中获取“EM核心靶点”的正常组与模型组样本的表达矩阵信息,绘制差异分组比较图,构建TFmRNA-miRNA网络,筛选其作用的核心靶点;第二部分进行动物实验验证。通过同种异体子宫内膜移植法建立EM大鼠模型,将模型大鼠分为模型组、中药组及阳性对照组,每组6只,并设置假手术组6只作为对照,灌胃治疗14 d后取材,对血清及内膜组织进行检测,采用酶联免疫吸附测定检测血清糖类抗原125(CA125)、血管内皮生长因子(VEGF)等相关指标水平,采用逆转录实时定量聚合酶链式反应法检测正常/异位内膜组织miR-199a-5p、低氧诱导因子1α(HIF-1α)、VEGF等相关分子mRNA的表达情况。结果通过生物信息学分析得出,在血管生成这一关键环节,扶正化瘀方可能通过下调HIF-1α、VCAM1、STAT3、SERPINE1,上调MMP2、PDCFRB表达起到干预EM血管生成,延缓异位病灶生长的作用,并构建“TF-m RNA-mi RNA网络”,经过动物实验验证,相比于模型组,中药组血清CA125、VEGF水平显著降低,异位病灶体积显著缩小,且miR-199a-5p表达升高,HIF-1α、VEGF表达降低[(9.99±1.01)U/mL vs(14.60±0.65)U/mL,P<0.05;(170.04±29.40)pg/mL vs(245.42±36.10)pg/mL,P<0.05;(6.41±2.11)mm^(3) vs(23.92±4.63)mm^(3),P<0.05;0.80±0.08 vs 0.02±0.01,P<0.05;1.28±0.06 vs 2.21±0.32,P<0.05;1.29±0.23 vs 3.79±0.80,P<0.05]。结论扶正化瘀方可能通过下调HIF-1α、VEGF等因子表达,干预血管生成这一关键环节,缩小EM异位病灶,延缓EM进一步发展。
